AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive the FDA has approved the first human trial of the company's lead drug Ampligen with interferon alfa-2b in treating cancer patients battling the coronavirus.
Equels says the new clinical trial will be conducted at Roswell Park Comprehensive Cancer Center, where a Phase 1/2b of the study will enroll around 40 patients in two stages.
Price: 2.02 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that data has been published detailing how its drug Ampligen could have a considerable impact on people living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when administered in the disease’s early...
Director Interviews
AIM Immunotech forms Phase 1/2a clinical trial agreement to fight...
Director Interviews
AIM ImmunoTech green-lit to import chronic fatigue syndrome drug...
Prev article
